Final Evidence Report and Meeting Summary ----------------------------------------- [https://icer-review.org/material/high-cholesterol-final-report/][1] New Evidence Update ------------------- [https://icer-review.org/material/pcks9-inhibitors-neu/][2] [https://icer-review.org/material/alirocumab-final-neu/][9] ---------- ## Action Guide for Clinicians, Payers, and Policymakers ## [https://icer-review.org/material/high-cholesterol-action-guide_cpp/][3] ## Action Guide for Patients ## [https://icer-review.org/material/high-cholesterol_action_guide_patients/][4] ---------- ## Publications ## [http://dx.doi.org/10.1001/jama.2016.11004][5] [http://dx.doi.org/10.1001/jamainternmed.2015.7248][6] [http://dx.doi.org/10.1001/jama.2017.9924][7] [https://dx.doi.org/10.7326/M17-3367][8] [1]: https://icer-review.org/material/high-cholesterol-final-report/ [2]: https://icer-review.org/material/pcks9-inhibitors-neu/ [3]: https://icer-review.org/material/high-cholesterol-action-guide_cpp/ [4]: https://icer-review.org/material/high-cholesterol_action_guide_patients/ [5]: http://dx.doi.org/10.1001/jama.2016.11004 [6]: http://dx.doi.org/10.1001/jamainternmed.2015.7248 [7]: http://dx.doi.org/10.1001/jama.2017.9924 [8]:https://dx.doi.org/10.7326/M17-3367 [9]: https://icer-review.org/material/alirocumab-final-neu/